Crohn’s disease is a chronic inflammatory condition of the lining of the gastrointestinal tract.
The inflammation caused by Crohn's disease often spreads beyond affected areas.
Crohn's disease can be both painful and debilitating, and sometimes may lead to life-threatening complications.
This clinical study is testing a novel approach for the treatment of Crohn’s disease by targeting the bacteria, Mycobacterium avium subsp. paratuberculosis (MAP), a potential cause of Crohn's disease. This study is called MAP US.
This study will randomize 270 participants and take place in approximately 120 doctors’ offices in the US, and in Canada, Israel, Australia, New Zealand and Poland.
Potential candidates will be men and women 18 to 75 years of age with moderately to severly active Crohn’s disease diagnosed more than six months ago.
The study will involve participation of up to 62 weeks.
Compensation is available.
More information for this study can be found by calling 03 9094 9543 or visiting www.MAPmyCrohns.com.
RHB-104-01_Press Release_ANZ_ 15-JAN-2015 Version 2